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FACTORS PREDICTING ALLOGENEIC PERIPHERAL BLOOD STEM CELL
(PBSC) MOBILIZATION AFTER G-CSF TREATMENT IN HEALTHY DONORS
Brissot, E.1, Chevallier, P.1, Guillaume, T.1, Delaunay, J.1, Ayari, S.1,
Saulquin, B.1, Flandrois, G.2, Devys, A.2, Stocco, V.2, Moreau, P.1,
Harousseau, J.L.1, Mohty, M.1 1CHU de Nantes, Nantes, France;
2Etablissement Francais du Sang (EFS), Nantes, France
Some healthy donors may show poor mobilization response to G-
CSF and poor CD341 apheresis yields. Therefore, identifying do-
nors at risk for poor mobilization could be of value in optimising
transplantation approaches. This single centre report analyzed fac-
tors associated with PBSC mobilization and yield in a homogeneous
caucasian population (n 5 95; 53% males) of healthy adult donors.
All donors received G-CSF dosed at 10 mg/kg/d for 5 days followed
by large volume leukapheresis. 69 donors (73%) were healthy sibling
donors, while 26 (27%) were healthy volunteer donors for HLA-
identical unrelated transplants. All donors were undergoing their
first PBSC mobilization. Donors’ demographic characteristics
were as follow (median; range): age, 47 (18–81) y., weight, 69 (43–
106) kg, height, 170(150–187) cm, body-mass index (BMI), 23.9
(15.2–35.7) kg/m2. As per institutional policy, the targeted total
number of CD341 stem cells was between 4 and 8 10e6/kg recip-
ient body weight to be collected in a maximum of 3 apheresis ses-
sions. Overall, the median number of collected CD341 cells was
6.25  10e6/kg (range, 1.7–16.6), with 16 donors (17%) yielding
less than 4  10e6/kg CD341 cells. In univariate analysis, female
gender, lower weight, height, pre-G-CSF and post G-CSF Hb
levels, and low CD341 cell counts prior to first apheresis, were as-
sociated with significantly lower total CD341 stem cells yields
(\6.25  10e6/kg). In multivariate analysis, male donor gender
and higher post-G-CSF CD341 cell counts prior to the first apher-
esis were most strongly associated with a higher total number of
collected CD341 stem cells (OR 5 6.17, 95%CI (2.39–15.93),
P5 0.0001; and OR5 3.95, 95%CI (1.53–10.19), P5 0.004 respec-
tively). Also, when considering the group of 16 ‘‘poor’’ mobilising
donors (CD341 stem cells yield\4 10e6/kg), inmultivariate anal-
ysis, we found that a higher post-G-CSF CD341 cell count prior to
the first apheresis was the strongest parameter significantly associ-
ated with a higher total number of collected CD341 stem cells
(OR5 6.36, 95%CI (1.68–24.15), P5 0.006). These results indicate
that a quick assessment of risk for poor mobilization response in
healthy donors can be achieved through simple demographic and
routine parameters. Knowledge of predictive factors for mobiliza-
tion to G-CSF may be of high interest, with the development of
newer mobilizing agents like CXCR4 antagonists.117
CORD BLOOD STORAGE FOLLOWING COLLECTION: IMPACT ON VOLUME
REDUCTION AND CRYOPRESERVATION
Morin, H.1, Wagner, E.2, Champagne, M.A.3 1CHU Sainte-Justine,
Montreal, QC, Canada; 2Centre Hospitalier Universitaire de Quebec,
Quebec, QC, Canada; 3Hema-Quebec, St-Laurent, QC, Canada
Delays from cord blood (CB) collection to processing and cryo-
preservation vary among CB banks and optimal CB storage length
and conditions are still poorly defined. Only about 25% of the
collected CB units contain a total nucleated cell (TNC) content
$1  109, providing enough cells to transplant a 40 kg recipient.
Our preliminary results suggest that CB is best stored at 4C for
up to 3 days without significant losses in cell numbers and viability.
We tested whether pre-cryopreservation CB storage conditions
impact cell recovery and viability after processing and cryopreserva-
tion. CB units were collected and processed and cryopreserved either
on the day of collection (day 0) or after a 3-day storage at 4C or
room temperature (RT). They were volume-reduced by buffy coat
separation (Optipress II) or red cell sedimentation (Hespan). Pro-
cessed CB units were cryopreserved and stored for 1 month before
thawing and washing, and were assessed for TNC, mononucleated
cell (MNC) and CD341 cell recovery, and CD451 and CD341
cell viability. Storage at RT for 3 days induced a significant loss in
TNC and MNC after processing whereas storage at 4C did not in-
duce a significant change compared to units processed on day 0. Both
Optipress II- and Hespan-processed CB units showed low CD451
cell viabilities when stored at RT (e.g. 64 6 10% at RT and 82 68% at 4C vs 986 2% on day 0, p\0.002 vs day 0 for the Optipress
group). Interestingly, CB units stored at RT for 3 days showed re-
duced TNC, MNC and CD341 cell recoveries and reduced
CD341 cell viability upon thawing and washing compared to units
cryopreserved on day 0 or stored at 4C for 3 days (e.g. CD341
cell viability in the Optipress group: 70 6 14% at RT, 87 6 10%
at 4C vs 846 5% on day 0, p\0,03 vs day 0). These results indicate
that prolonged storage at RT prior to cryopreservation can nega-
tively impact CB cell recovery and viability after processing and
upon thawing and washing of cryopreserved units.118
TREATMENT OF THREATENING REJECTION AFTER UMBILICAL CORD
BLOOD TRANSPLANTATION WITH EX VIVO EXPANDED CB DERIVED T
CELLS
Uhlin, M., Okas, M., Gertow, J., Ringden, O., Mattsson, J. Karolinska
Institutet, Stockholm, Sweden
For patients lacking a human leukocyte antigen (HLA)-matched
donor, umbilical cord blood (UCB) is a promising source of hema-
topoetic stem cells. Greater HLA disparity can be tolerated between
the recipient and donor UCB compared with bone marrow or
peripheral blood stem cells because of the naive and immature phe-
notype of UCB derived T cells. The risk of rejection is increased
after UCB transplantation. After HLA-identical sibling or matched
unrelated SCT the graft-versus-leukemia (GVL) effect may be in-
creased by donor lymphocyte infusion (DLI) after SCT. However,
after UCB transplantation DLI is not possible. This raised the ques-
tion of whether ex vivo expanded CB lymphocytes (CBL) also can be
used as a tool for adoptive immunotherapy after CB SCT. We have
managed to establish a protocol for massive expansion of CB derived
T cells making them usable in the clinic suitable for DLI after CB
transplantation. We have further been able to show that the expan-
sion protocol doesn’t skew the T cell population regarding the phe-
notype, CD4:CD8 ratio as well as TCR usage profile measured by
spectratyping. By activating the cells we have further investigated
and confirmed the expanded T cells capacity to efficiently produce
pro-inflammatory cytokines and respond in an allogeneic setting.
We have now tried expanded CBLs in an adult patient with AML
with threatening rejection after double UCB transplantation. The
patient received Bu/Cy and ATG as conditioning therapy. He was
transplanted with double UCB with a total nucleated cell dose of
5  107/kg. Both UCB units were 5/6 matched for HLA-A,-B and
-DRB1 with low resolution HLA-typing. Chimerism analysis one
month after transplant showed mixed chimerism in T-, B- and mye-
loid cells of both donor units and recipient. At four months after
transplant the patient had 85% recipient cells in both T cells and
myeloid cells indicating a threatening rejection. However, in bone
marrow CD341 cells were 90% of donor origin. Due to anticipated
rejection the patient was treated with expanded CBLs, 5 103/kg at
4 months, 1 104/kg at 5 months and 1 105/kg at six months. Im-
munusuppression was tapered at six months. The immunemodula-
tory treatment was well tolerated with no development of GVHD.
So far no change in chimeric pattern has been shown. The immune-
modulatory treatment will be continued with increasing doses of
CBLs.119
STANDARDIZATION OF T CELL (CD31) DOSE FOR ALLOGENEIC
PERIPHERAL BLOOD STEM CELL GRAFTS
Innis-Shelton, R., Tilden, A., Ashraf, K., Vaughan, W.P., Lamb, L.S.
University of Alabama at Birmingham, Birmingham, AL
The number of CD31 cells collected from donors varies widely
and no significant attempts have been made to standardize the graft
T cell content within the different categories of stem cell sources.
Preliminary data from our center have shown that that administra-
tion of dexamethasone during the last three days of G-CSF mobili-
zation reduces the donor T cell content of the graft by approximately
0.5 log, also resulting in a significant decrease in the incidence and
severity of acute GvHD. Based on these findings, we have developed
a procedure to standardize the graft to deliver a PBSC product with
a T cell dose of 3.0 6 0.5  107 CD31 cells/kg recipient body
Poster Session-I 47weight, a T cell dose comparable to bone marrow transplant, in
a complete product with the exception of incidental losses that occur
during the process of T cell depletion (TCD). Following collection,
CD31T cells are enumerated by flow cytometry and a portion of the
product containing a dose of 3.0  107 CD31 cells/kg is set aside.
The remainder of the product is depleted of T cells by a two-step
method where the cells are first labeled with the anti-CD3monoclo-
nal antibody OKT3 attached to ferromagnetic microspheres. The
product is then incubated for 30min, washed twice, and passed
through a magnetized bead matrix that isolates the CD31 T cells
(CliniMACS; Miltenyi Biotec, Duarte CA). The T cell depleted
product is then combined with the set aside portion of the product
containing 3.0  107 CD31 cells/kg for the transplant. Three sepa-
rate procedures revealed 3.2 6 0.7 log TCD for the depleted prod-
uct. Recovery of other cellular components in the TCD product was
as follows: B cells 75.4% 6 17.5, NK cells 33.9% 6 30.3, CD346
cells 42.0% 6 8.0. Viability of the TCD product was 97.1% 6 1.9
and sterility assessment revealed all cultures to be free of organisms
following 14 days culture. Taken together, these data confirm
that partial TCD can be accomplished in a closed system allowing
standardization of graft T cell content.120
THE IMPORTANCE OF GRAFT CELL COMPOSITION TO OUTCOME AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION
Svenberg, P.1,3, Ringden, O.1, 2, Uzunel, M.1 1,2,3Karolinska University
Hospital, Huddinge, Sweden
Background: Stem cell dose has been shown to be important for
outcome in patients who undergo stem cell transplantation (SCT).
Grafts may contain varying amounts of different cell populations like
CD31, CD191, CD561, CD41 and CD81 immunocompetent
cells, whose role for clinical outcome is less clear.
Patients and Methods: We analyzed 591 patients who under-
went SCT at Karolinska University Hospital, Huddinge between
1998 to 2007 and correlated FACS results of the above mentioned
cell populations to clinical outcome. Most patients (76%) had he-
matological malignancies. 58% of the patients received a myeloa-
blative conditioning regimen, 62% were given peripheral blood
stem cells (PBSC) and in 58% of the transplants an unrelated donor
was used.
Results: As expected, PBSC contained much higher levels of all
different cell populations as compared to BM. We found that pa-
tients reciving high numbers of CD41, and CD81 cells had signif-
icantly more rapid engraftment. Also, a CD41 level above 200 
10(6)/kg was correlated to higher risk of developing acute GVHD
grades II-IV (41%) as compared to patients receiving below this level
(24%) (p\0,037).While the incidence of bacteria sepsis was lower in
patients receiving a high number of cell dose (CD3, CD19, CD56),
no correlation between cell dose and CMV reactivation was found.
Relapse free- and overall survivals were not significantly affected
by the different cell populations.
Conclusion: Grafts containing high numbers of CD41 cells is
a risk factor for developing severe acute GVHD but survival rates
were not significantly correlated to graft composition.HEMATOPOIESIS/MESENCHYMAL CELLS
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HLA MISMATCHED MSC SUPPRESS T LYMPHOCYTE ALLORESPONSES IN
VITRO AND DO NOT INDUCE IMMUNOLOGICAL MEMORY IN RECIPIENTS
OF MSC INFUSION
Sundin, M.1, Barrett, J.2, Ringden, O.1, Uzunel, M.1, Lonnies, H.1,
Dackland, A.-L.3, Christensson, B.3, Le Blanc, K.4 1Karolinska Institutet,
Stockholm, Sweden; 2National Institute of Health, Bethesda, MD; 3Kar-
olinska Institutet, Stockholm, Sweden; 4Karolinska Institutet and Karolin-
ska University Hospital Huddinge, Stockholm, Sweden
Multipotent mesenchymal stromal cells (MSC) are increasingly
used to treat refractory graft-versus-host-disease and other com-
plications in HLA-matched and mismatched hematopoietic stem
cell transplantation (HSCT) patients. We evaluated immunoge-nicity of human allogeneic MSC infused post-transplant to
HLA-mismatched, i.e. patients undergoing HSCT.We compared
recipient lymphocyte response to MSC and peripheral blood lym-
phocytes (PBL) from theMSC or third party donors before and af-
ter infusion, and lymphocyte responses to MSC and to PBL from
the MSC donor in primary and secondary challenge using 3H-ty-
midine. MSC recipients displayed in median responses less than
500 counts per minute (CPM) to infused third party MSC 1
week to 6 months following infusion. However, the recipients re-
sponded normally to MSC donor lymphocytes, .1000 CPM
(p\0.005), and third party lymphocytes, .5000 CPM
(p\0.005). MSC failed to prime responder lymphocytes to rechal-
lenge with PBL, as the responses was \10 000 versus .30 000
CPM for the corresponding control (p\0.05). On MSC rechal-
lenge of lymphocytes primed with PBL from the MSC donor,
only responses\500 CPM occurred. MSC upregulated lympho-
cyte gene expression of CD25, IFN-g, FoxP3, CTLA-4 and IL-
10 upon MSC/PBL co-culture and MSC presence in mixed
lymphocyte cultures. Unprimed and primed responder lympho-
cytes expanded and proliferated poorly to MSC as stimuli, evalu-
ated by flow cytometry. The MSC failed to induce CD251
(activated) or CD571 (effector) CD41 or CD81 subsets and
only inconsistently induced FoxP31 regulatory T lymphocytes.
These results confirm in vivo and in vitro that infused MSC are
weakly immunogenic and do not induce significant immunological
memory in HLA-disparate recipients.122
DOUBLE CORD BLOOD TRANSPLANTATION (CBT) WITH EX-VIVO EX-
PANSION (EXP) OF ONE UNIT UTILIZING A MESENCHYMAL STROMAL
CELL (MSC) PLATFORM
de Lima, M.1, McNiece, I.2, McMannis, J.1, Hosing, C.1, Kebraei, P.1,
Komanduri, K.1, Worth, L.1, Staba, S.1, Cooper, L.1, Petropolous, D.1,
Lee, D.1, Jones, R.1, Nieto, Y.1, Andersson, B.1, Korbling, M.1,
Alousi, A.1, Qazilbash, M.1, Popat, U.1, Khouri, I.1, Bollard, C.3,
Leen, A.3, Rondon, G.1, Molldrem, J.1, Champlin, R.1, Simmons, P.4,
Shpall, E.1 1University of Texas M.D. Anderson Cancer Center;
2University of Miami; 3Baylor College of Medicine; 4University of Texas
Institute of Molecular Medicine
Delayed or failed engraftment is a frequent complication of CBT.
We developed an approach that involves ex vivo co-culture of CB
mononuclear cells with third party marrow derived MSCs. Patients
must have 2 CB units matched in at least 4/6 HLA antigens, with
a minimum of 1 107 TNC/Kg per unit. A family member matched
in at least 2/6 antigens or more serves as the marrow-derived MSC
donor.
Methods: Diagnoses: AML/MDS (N 5 4), ALL (N 5 1), and
CLL (N5 1).One patientwas inCR and 5 had active disease (1 failed
a previous CBT). Preparative regimen: myeloablative melphalan
(140mg/m2), thiotepa (10mg/kg), fludarabine (160mg/m2), and rab-
bit ATG (3 mg/kg). GVHD prophylaxis: tacrolimus and MMF.
Median weight was 57 Kg (range, 14–79). Donor-recipient HLA
matching was 5 of 6 in 35% of the cases and 4 of 6 in 65%. Ex-
vivo EXP: 100 ml of marrow was aspirated from the family donor
and MSCs were generated in 10 T175 flasks. The CB unit with
the lowest TNC dose was thawed, and placed into flasks containing
confluent layers of MSCs in EXP media with SCF, FLT3, G-CSF
and TPO. After 7 days at 37C, the non-adherent cells were re-
moved, and placed into one-liter Teflon-coated culture bags and cul-
tured for an additional 7 days (14 days total); 50 ml of media/growth
factors was added to the flasks to culture the remaining adherent
layer during that time period. On day 14 the cells were washed and
infused along with a 2nd unmanipulated unit.
Results: There were no toxicities attributable to EXP. The me-
dian fold EXP was 12 (1–13) for TNC and 12 (0–27) for CD341
cells. Median time to neutrophil and platelet engraftment was
14.5 days (12–23) and 31 days (25–51). All patients (n 5 6)
engrafted neutrophils and platelets and became complete donor(s)
chimeras. Chimerism: 1 unit dominated in all patients; 2 patients
have mixed donors chimerism 4 months after CBT, with 5%
and 20% of the EXP unit contributing to hemopoiesis. Three pa-
tients had no evidence of EXP unit-derived hemopoiesis after day
130, while 1 patient is 100% donor but the contributing unit
